Table 2 Patient characteristics for patients with postoperative WHO performance status 0–2 vs. WHO performance status > 2
From: Significance of poor performance status after resection of colorectal liver metastases
WHO performance status, 0–2 N = 210 | WHO performance status, > 2 N = 74 | P value | |
|---|---|---|---|
Male gender | 125 (59.5%) | 51 (68.9%) | 0.152 |
Age, years | 68 (62–73) | 68 (62–73) | 0.224 |
Smoking | 49 (23.3%) | 10 (13.5%) | 0.073 |
Diabetes mellitus | 22 (10.5%) | 9 (12.2%) | 0.689 |
Body mass index (kg/m2) | 25 (23–28) | 25 (23–27) | 0.969 |
ASA grade 3–4 | 53 (25.2%) | 31 (41.9%) | 0.007 |
Preoperative albumin (g/l) | 38 (35–40) | 38 (35–40) | 0.452 |
Preoperative creatinine (μmol/l) | 73 (63–83) | 80 (66–95) | 0.052 |
Rectal primary | 71 (35.5%) | 25 (36.8%) | 0.851 |
Primary T4 | 45 (24.7%) | 12 (19.7%) | 0.420 |
Node positive primary | 116 (63.7%) | 47 (77.1%) | 0.056 |
Synchronous disease | 116 (58.0%) | 30 (44.1%) | 0.047 |
Synchronous lung and liver metastases | 11 (5.7%) | 11 (16.4%) | 0.006 |
> 1 tumour | 125 (60%) | 49 (66%) | 0.353 |
Tumour size > 50 mm | 22 (10.5%) | 8 (10.8%) | 0.936 |
Preoperative chemotherapy | 123 (58.6%) | 41 (55.4%) | 0.635 |
Preoperative chemotherapy cycles | 5 (4–6) | 4 (3–5) | 0.600 |
Preoperative chemotherapy > 6 cycles | 16 (7.7%) | 8 (10.8%) | 0.416 |
Operation time (hours) | 5 (3–6) | 5 (3–7) | 0.251 |
Operative bleeding (ml) | 400 (200–600) | 400 (200–900) | 0.145 |
Major resection | 94 (44.8%) | 33 (44.6%) | 0.980 |
Hospital stay (days) | 7 (6–8) | 7 (6–10) | 0.214 |
Morbidity (Clavien-Dindo ≥ 3) | 19 (9.0%) | 16 (21.6%) | 0.005 |